FDA grants 510(k) approval for BioPlex 2200 Syphilis Total & RPR assay to diagnosis syphilis infection. Bio-Rad Laboratories
Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, announced it has received FDA 510(k) clearance for its BioPlex 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of syphilis infection.
The release of the BioPlex 2200 Syphilis Total & RPR assay is the latest offering in Bio-Rad�s growing infectious disease menu for the BioPlex 2200 System, a fully automated multiplex technology platform. The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or �multiplex� multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.
Related news and insights
Anavex Life Sciences Corp. announced positive topline results from its Phase IIb/III ANAVEX2-73-AD-004 clinical trial of oral ANAVEX2 73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD).
Vaxxinity announced today that its next generation UB 612 COVID-19 vaccine, when administered as a single heterologous booster dose, elicited strong neutralizing antibodies against SARS-CoV-2 when compared head-to-head to three globally authorized platform vaccines administered as homologous boosters, confirming success in meeting the primary and key secondary immunogenicity endpoints of its pivotal global Phase III trial.